Method for producing p53 amyloid aggregate
By incubating p53 protein monomers with ionic compounds like thiocyanate or iodide, the method effectively promotes p53 amyloid aggregate formation, overcoming inefficiencies in existing methods and enabling the production of specific antibodies.
Patent Information
- Application Number
- JP2023077995
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Existing methods are inefficient in promoting the formation of p53 amyloid aggregates while suppressing amorphous aggregates under physiological conditions.
A method involving the incubation of a reaction solution containing p53 protein monomers with at least one ionic compound, such as thiocyanate or iodide, at specific concentrations and temperatures to enhance the production of p53 amyloid aggregates.
This method efficiently produces p53 amyloid aggregates with a higher ratio of amyloid to amorphous aggregates, facilitating the development of p53 amyloid aggregate-recognizing antibodies with enhanced specificity.
Smart Images

Figure 2024162466000001 
Figure 2024162466000002 
Figure 2024162466000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing p53 amyloid aggregates, and the like. [Background technology]
[0002] The protein p53 is the product of the tumor suppressor gene TP53, and is a transcription factor that prevents cells from becoming cancerous by inducing gene repair proteins and apoptosis when DNA is damaged. The DNA-binding domain, one of the domains of p53, has the property of aggregation, and it is known that p53 forms two types of aggregates (amorphous aggregates and amyloid aggregates) with different structures and properties from this domain. Furthermore, it is thought that the formation of these aggregates inhibits the function of p53, leading to cancer. [Prior art documents] [Non-patent literature]
[0003] [Non-Patent Document 1] Hibino, E., Tenno, T., and Hiroaki, H. (2022) Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity. Front. Mol. Biosci. 10.3389 / fmolb.2022.869851 Summary of the Invention [Problem to be solved by the invention]
[0004] Under physiological conditions in a test tube, most of the aggregates formed from p53 monomers are amorphous p53 aggregates. Non-Patent Document 1 reports that the addition of potassium chloride to a test tube containing wild-type p53 monomers suppresses the formation of amorphous p53 aggregates, but potassium chloride cannot promote the formation of amyloid aggregates from wild-type p53 monomers.
[0005] An objective of the present invention is to provide a more efficient method for producing p53 amyloid aggregates. [Means for solving the problem]
[0006] In view of the above problems, the present inventors have conducted intensive research and found that the above problems can be solved by a method for producing p53 amyloid aggregates, comprising incubating a reaction solution containing a p53 protein monomer and at least one ionic compound selected from the group consisting of thiocyanate and iodide. Based on this finding, the present inventors have conducted further research and completed the present invention. That is, the present invention encompasses the following aspects.
[0007] Item 1. A method for producing p53 amyloid aggregates, comprising incubating a reaction solution containing a p53 protein monomer and at least one ionic compound selected from the group consisting of thiocyanate and iodide.
[0008] Item 2. The method according to Item 1, wherein the reaction solution contains a thiocyanate.
[0009] Item 3. The method according to Item 1, wherein the concentration of the ionic compound in the reaction solution is 10 mM or more.
[0010] Item 4. The method according to Item 1, wherein the concentration of the ionic compound in the reaction solution is 50 mM or more.
[0011] Item 5. The method according to any one of Items 1 to 4, wherein the temperature of the reaction solution during incubation is 10 to 50°C.
[0012] Item 6. The method according to any one of Items 1 to 4, wherein the incubation time is 1 minute or longer.
[0013] Item 7. A composition containing p53 amyloid aggregates, in which the ratio (ThT / ANS) of the fluorescence intensity derived from thioflavin T (ThT) to the fluorescence intensity derived from 8-(phenylamino)-1-naphthalenesulfonic acid (ANS) is 0.5 or more.
[0014] Item 8. A p53 amyloid aggregate-containing composition according to Item 7, which contains at least one ionic compound selected from the group consisting of thiocyanates and iodides.
[0015] Item 9. The p53 amyloid aggregate-containing composition according to Item 7, wherein the ratio is 1.0 or more.
[0016] Item 10. A p53 amyloid aggregate-containing composition obtained by the production method according to any one of items 1 to 4.
[0017] Item 11. A method for producing a p53 amyloid aggregate-recognizing antibody, comprising using the p53 amyloid aggregate-containing composition according to any one of items 7 to 10 as an immunogen.
[0018] Item 12. A p53 amyloid aggregate-recognizing antibody obtained by the production method according to Item 11.
[0019] Item 13. A method for evaluating a test antibody, comprising contacting the test antibody with the p53 amyloid aggregate-containing composition according to any one of items 7 to 10.
[0020] Item 14. A method for screening for a p53 amyloid aggregate-recognizing antibody, which comprises contacting a test antibody with the p53 amyloid aggregate-containing composition according to any one of items 7 to 10.
[0021] Item 15. A p53 amyloid aggregate-recognizing antibody selected by the screening method according to item 14. Effect of the Invention
[0022] According to the present invention, it is possible to provide a more efficient method for producing p53 amyloid aggregates. Furthermore, according to the present invention, it is also possible to provide a p53 amyloid aggregate-containing composition, a method for producing a p53 amyloid aggregate-recognizing antibody, a p53 amyloid aggregate-recognizing antibody, etc. [Brief description of the drawings]
[0023] [Figure 1] The graph shows the measurement results of the fluorescence intensity derived from ANS (left graph) and the fluorescence intensity derived from ThT (right graph) when KSCN was added (Test Example 1). The horizontal axis indicates the time elapsed from the start of incubation. The vertical axis indicates the relative value when the fluorescence intensity of the control (0 mM, 60 minutes) is set to 1. The legend indicates the KSCN concentration in the reaction solution. [Diagram 2] The graph shows the measurement results of the fluorescence intensity derived from ANS (left graph) and the fluorescence intensity derived from ThT (right graph) when NaSCN was added (Test Example 2). The horizontal axis shows the elapsed time from the start of incubation. The vertical axis shows the relative value when the fluorescence intensity of the control (0 mM, 60 minutes) is set to 1. The legend shows the NaSCN concentration in the reaction solution. [Diagram 3] The graph shows the measurement results of the fluorescence intensity derived from ANS (left graph) and the fluorescence intensity derived from ThT (right graph) when KI was added (Test Example 2). The horizontal axis shows the elapsed time from the start of incubation. The vertical axis shows the relative value when the fluorescence intensity of the control (0 mM, 60 minutes) is set to 1. The legend shows the KI concentration in the reaction solution. [Figure 4] The measurement results of the ThT / ANS ratio when each additive (KSCN, NaSCN, KI, or NaI) was added are shown (Test Example 3). The horizontal axis shows the additive, and "non-additive" shows the case without any additive. [Diagram 5] 1 shows the results of measuring the absorbance of the centrifugal supernatant of the reaction solution before incubation and after incubation when KSCN was added (Test Example 4). [Figure 6]Transmission electron microscopic images of the samples after incubation are shown for the cases where KSCN was not added (under physiological conditions) and where it was added (this method) (Test Example 5). [Figure 7] Photographs of dot blots using a self-made antibody (A) and a commercially available p53 antibody (B) using the produced p53 amyloid aggregates as an antigen, and the ratio of the staining intensity of the dots of each aggregate (p53 amorphous, p53 amyloid) to the staining intensity of p53 monomer (C) are shown (Test Example 6). [Figure 8] FIG. 13 shows a transmission electron microscope image of a sample after incubation in the case where KSCN was added (Test Example 7). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] 1.Definition In this specification, the expressions "contain" and "comprise" include the concepts of "contain", "include", "consist essentially of" and "consist only of".
[0025] As used herein, the "identity" of an amino acid sequence refers to the degree of amino acid sequence agreement between two or more comparable amino acid sequences. Thus, the higher the agreement between two amino acid sequences, the higher the identity or similarity between those sequences. The level of identity of an amino acid sequence can be determined, for example, using the sequence analysis tool FASTA with default parameters. Alternatively, it can be determined using the BLAST algorithm by Karlin and Altschul (Karlin S, Altschul SF. "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes" Proc Natl Acad Sci USA. 87: 2264-2268 (1990); Karlin S, Altschul SF. "Applications and statistics for multiple high-scoring segments in molecular sequences" Proc Natl Acad Sci USA. 90: 5873-7 (1993)). A program called BLASTX based on such a BLAST algorithm has been developed. Specific techniques for these analysis methods are known and can be found on the National Center of Biotechnology Information (NCBI) website (http: / / www.ncbi.nlm.nih.gov / ). The "identity" of a base sequence is also defined in the same manner as above.
[0026] In this specification, an amino acid mutation specifically refers to an amino acid deletion, substitution, insertion, or addition.
[0027] In this specification, "conservative substitution" means that an amino acid residue is substituted with an amino acid residue having a similar side chain. For example, substitution between amino acid residues having basic side chains such as lysine, arginine, and histidine is considered to be conservative substitution. In addition, substitution between amino acid residues having acidic side chains such as aspartic acid and glutamic acid; amino acid residues having non-charged polar side chains such as glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine; amino acid residues having non-polar side chains such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan; amino acid residues having β-branched side chains such as threonine, valine, and isoleucine; and amino acid residues having aromatic side chains such as tyrosine, phenylalanine, tryptophan, and histidine are also considered to be conservative substitutions.
[0028] In this specification, amino acid substitution mutations may be indicated by the single letter code of the amino acid before the mutation + the amino acid number counted from the N-terminal amino acid + the single letter code of the amino acid after the mutation. For example, "AnnV" indicates a substitution mutation of alanine, the nnth amino acid from the N-terminus, with valine.
[0029] 2. Method for producing p53 amyloid aggregates In one aspect, the present invention relates to a method for producing p53 amyloid aggregates (sometimes referred to as the "aggregate production method of the present invention" in this specification), which comprises incubating a reaction solution containing a p53 protein monomer and at least one ionic compound selected from the group consisting of thiocyanate and iodide. This will be described below.
[0030] The p53 protein monomer is a raw material for the aggregate production method of the present invention, and is a p53 protein that does not form aggregates (i.e., a component of aggregates). The p53 protein is known to have the property of forming a dimer via the DNA binding domain, and is also known to have the property of forming a tetramer via the tetramerization domain. The "p53 protein monomer" of the present invention includes not only one molecule of p53 protein, but also the above dimer and tetramer.
[0031] The species from which the p53 protein is derived is not particularly limited, and examples include various mammals such as humans, monkeys, mice, rats, dogs, cats, rabbits, pigs, horses, cows, sheep, goats, and deer.
[0032] The gene encoding the p53 protein is known, for example, in the case of humans, the gene is the gene with NCBI Gene ID: 7157, and in the case of mice, the gene is the gene with NCBI Gene ID: 22059. Genes of other species are also known, or can be easily identified based on the base sequence of a known gene or the amino acid sequence encoded by the base sequence, according to or in accordance with a known method. The amino acid sequence of the p53 protein is also already known, or can be easily identified based on gene information.
[0033] The p53 protein is not particularly limited as long as it contains a domain (DNA-binding domain) involved in aggregate formation, and may be not only a wild-type but also one containing an amino acid sequence containing a mutation relative to the wild-type amino acid sequence. Such mutations include deletions and amino acid substitutions at sites other than the DNA-binding domain, and mutations in the DNA-binding domain. Examples of the latter mutations include various mutations known to affect aggregate formation, such as R175H, Y220C, M237I, G245S, R248Q, R249S, R242W, and R273C in the amino acid sequence of the wild-type human p53 protein shown in SEQ ID NO:1.
[0034] The DNA-binding domain is publicly known or can be easily identified according to publicly known information. For example, the DNA-binding domain in the amino acid sequence of wild-type human p53 protein shown in SEQ ID NO: 1 is the region from amino acid number 94 to amino acid number 291 (SEQ ID NO: 2).
[0035] In one embodiment of the invention, the p53 protein can be a p53 protein that lacks a mutation in the DNA binding domain that affects aggregate formation (eg, comprises a wild-type DNA binding domain).
[0036] Preferred specific examples of the p53 protein include the protein described in (A) below and the protein described in (B) below: (A) a p53 protein comprising the amino acid sequence shown in SEQ ID NO: 1 or 2, and (B) a p53 protein having an amino acid sequence having 85% or more identity with the amino acid sequence shown in SEQ ID NO: 1 or 2 and capable of forming amyloid aggregates. At least one selected from the group consisting of:
[0037] In the above (B), the identity is more preferably 90% or more, even more preferably 95% or more, and even more preferably 98% or more.
[0038] An example of the protein described in (B) above is, for example, (B') a p53 protein having an amino acid sequence in which one or more amino acids have been substituted, deleted, added, or inserted relative to the amino acid sequence shown in SEQ ID NO: 1 or 2 and having the ability to form amyloid aggregates. Examples include:
[0039] In the above (B'), "plural" means, for example, 2 to 40, preferably 2 to 20, more preferably 2 to 10, and even more preferably 2 or 3.
[0040] The ability to form amyloid aggregates can be evaluated according to the method described later in Test Example 1, etc. When the intensity of fluorescence derived from ThT increases after the start of incubation, it can be determined that the substance has the ability to form amyloid aggregates.
[0041] The p53 protein may have another amino acid sequence, such as a secretory signal sequence, a protein tag, a fluorescent protein, a luminescent protein, a signal sequence such as a protease recognition sequence (such as a TEV protease recognition sequence), or a peptide added thereto, so long as the amyloid aggregate-forming ability is not significantly impaired. Examples of protein tags include biotin, His tag, FLAG tag, Halo tag, MBP tag, HA tag, Myc tag, V5 tag, and PA tag.
[0042] The p53 protein may be chemically modified so long as its ability to form amyloid aggregates is not significantly impaired.
[0043] The p53 protein has a C-terminus that consists of a carboxyl group (-COOH) and a carboxylate group (-COO - ), amide (-CONH2) or ester (-COOR).
[0044] Here, R in the ester is, for example, C such as methyl, ethyl, n-propyl, isopropyl, and n-butyl. 1-6 Alkyl groups; for example, cyclopentyl, cyclohexyl, etc. 3-8 Cycloalkyl groups; for example, C phenyl, α-naphthyl, etc. 6-12 Aryl groups; for example, phenyl-C such as benzyl and phenethyl 1-2 Alkyl groups: α-naphthyl-C such as α-naphthylmethyl 1-2 C such as alkyl group 7-14 Aralkyl groups, pivaloyloxymethyl groups, etc. are used.
[0045] The p53 protein may be amidated or esterified at a carboxyl group (or carboxylate) other than the C-terminus. In this case, the ester may be, for example, the C-terminus ester described above.
[0046] The p53 protein may be in the form of a salt with an acid or a base. The salt is not particularly limited, and both acid salts and basic salts can be used. Examples of acid salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate; organic acid salts such as acetate, propionate, tartrate, fumarate, maleate, malate, citrate, methanesulfonate, and paratoluenesulfonate; amino acid salts such as aspartate and glutamate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.
[0047] The p53 protein may be in the form of a solvate. The solvent is not particularly limited, and examples thereof include water, ethanol, glycerol, and acetic acid.
[0048] The p53 protein can be easily produced according to its amino acid sequence by known genetic engineering techniques, such as PCR, restriction enzyme digestion, DNA ligation, in vitro transcription / translation, and recombinant protein production techniques.
[0049] The p53 protein monomer may be one type alone or two or more types in combination.
[0050] The concentration of the p53 protein monomer in the reaction solution is not particularly limited, and is, for example, 0.01 μM or more, preferably 0.1 μM or more, more preferably 0.1 to 1 mM, even more preferably 0.2 to 200 μM, still more preferably 0.4 to 100 μM, particularly preferably 1 to 50 μM, and particularly preferably 1 to 20 μM.
[0051] The reaction liquid contains at least one ionic compound selected from the group consisting of thiocyanates and iodides.
[0052] The above ionic compounds may be used alone or in combination of two or more kinds.
[0053] The concentration of the ionic compound in the reaction solution is not particularly limited. The present inventors have found that the presence of the ionic compound in the reaction solution exerts a concentration-dependent effect of promoting the formation of p53 amyloid aggregates and suppressing the formation of p53 amorphous aggregates, and therefore, if the ionic compound is present, the above effect should be exerted regardless of its amount. From the viewpoint of the effect of promoting the formation of p53 amyloid aggregates and the effect of suppressing the formation of p53 amorphous aggregates, the concentration is preferably 1 mM or more, more preferably 10 mM or more, even more preferably 20 mM or more, even more preferably 50 mM or more, particularly preferably 100 mM or more, particularly preferably 150 mM or more, and particularly preferably 180 mM or more. The upper limit of the concentration is not particularly limited, and can be, for example, the solubility of the ionic compound, 2000 mM, 1500 mM, 1000 mM, 800 mM, or 600 mM.
[0054] Thiocyanates are ionic compounds containing thiocyanate ions, and are not particularly limited thereto. Examples of thiocyanates include potassium thiocyanate, sodium thiocyanate, ammonium thiocyanate, and guanidine thiocyanate. Among these, potassium thiocyanate and sodium thiocyanate are particularly preferred from the viewpoint of promoting the formation of p53 amyloid aggregates and inhibiting the formation of p53 amorphous aggregates.
[0055] The thiocyanate may be one type alone or two or more types in combination.
[0056] When the reaction solution contains a thiocyanate, the concentration of the thiocyanate in the reaction solution is not particularly limited. The present inventors have found that the presence of a thiocyanate in the reaction solution exerts a concentration-dependent effect of promoting the formation of p53 amyloid aggregates and suppressing the formation of p53 amorphous aggregates, and therefore, if a thiocyanate is present, the above effect should be exerted regardless of its amount. From the viewpoint of the effect of promoting the formation of p53 amyloid aggregates and the effect of suppressing the formation of p53 amorphous aggregates, the concentration is preferably 1 mM or more, more preferably 10 mM or more, even more preferably 20 mM or more, even more preferably 50 mM or more, particularly preferably 100 mM or more, particularly preferably 150 mM or more, and particularly preferably 180 mM or more. The upper limit of the concentration is not particularly limited, and can be, for example, the solubility of the thiocyanate, 2000 mM, 1500 mM, 1000 mM, 800 mM, or 600 mM.
[0057] Iodide is an ionic compound containing iodine ion, and is not particularly limited thereto. Examples of iodide include potassium iodide, sodium iodide, ammonium iodide, etc. Among these, from the viewpoint of promoting the formation of p53 amyloid aggregates and inhibiting the formation of p53 amorphous aggregates, etc., potassium iodide and sodium iodide are particularly preferred.
[0058] The iodide may be one type alone or a combination of two or more types.
[0059] When the reaction solution contains iodide, the concentration of iodide in the reaction solution is not particularly limited. The present inventors have found that the presence of iodide in the reaction solution exerts a concentration-dependent effect of promoting the formation of p53 amyloid aggregates and suppressing the formation of p53 amorphous aggregates, and therefore, if iodide is present, the above effects should be exerted regardless of its amount. From the viewpoint of the effect of promoting the formation of p53 amyloid aggregates and the effect of suppressing the formation of p53 amorphous aggregates, the concentration is preferably 1 mM or more, more preferably 10 mM or more, even more preferably 20 mM or more, even more preferably 50 mM or more, particularly preferably 100 mM or more, especially more preferably 150 mM or more, and particularly preferably 180 mM or more. The upper limit of the concentration is not particularly limited, and can be, for example, the solubility of iodide, 1000 mM, 800 mM, or 600 mM.
[0060] Among the above ionic compounds, thiocyanate is particularly preferred from the viewpoints of promoting the formation of p53 amyloid aggregates and inhibiting the formation of p53 amorphous aggregates.
[0061] The solvent of the reaction solution is not particularly limited as long as it is capable of forming aggregates without denaturing the p53 protein monomer. For example, water can be used as the solvent. A mixed solvent of water and an organic solvent (e.g., alcohol, etc.) can also be used.
[0062] The solvent has, for example, a water content of, relative to 100% by volume of the solvent, for example, 50% by volume or more, preferably 70% by volume or more, more preferably 80% by volume or more, even more preferably 90% by volume or more, still more preferably 95% by volume or more, and particularly preferably 99% by volume or more.
[0063] The pH of the reaction solution is not particularly limited as long as the p53 protein monomer is not denatured and can form aggregates. The pH is preferably 5 to 9, more preferably 7.0 to 8.0.
[0064] The reaction solution preferably contains a buffer for adjusting or controlling the pH. The buffer is not particularly limited, but examples thereof include HEPES buffer, Tris buffer, phosphate buffer, MOPS buffer, etc.
[0065] The reaction solution preferably contains a reducing agent (e.g., dithiothreitol (DTT), TCEP, β-mercaptoethanol, etc.) for the purpose of protecting disulfide bonds. When the reaction solution contains a reducing agent, the concentration of the reducing agent in the reaction solution is not particularly limited. In one embodiment of the present invention, the concentration is, for example, 0.1 to 25, preferably 0.2 to 10, and more preferably 0.5 mM to 2 mM.
[0066] In addition to the above, the reaction solution may contain additives as long as the formation of p53 amyloid aggregates is not significantly inhibited. The additives are not particularly limited, but may include, for example, fluorescent dyes for monitoring the formation of aggregates. Examples of such fluorescent dyes include the dyes used in the test examples described below.
[0067] Incubation is carried out by leaving the reaction solution at a certain temperature range.
[0068] The temperature of the reaction solution during incubation is not particularly limited as long as the p53 protein monomer is not denatured and can form aggregates, and may be, for example, 10 to 50°C, preferably 20 to 45°C, more preferably 30 to 42°C, and even more preferably 35 to 40°C.
[0069] The incubation time is not particularly limited as long as p53 amyloid aggregates are produced. The incubation time is, for example, 1 minute or more, preferably 5 minutes or more, more preferably 10 minutes or more, even more preferably 20 minutes or more, even more preferably 30 minutes or more, and particularly preferably 45 minutes or more. The upper limit of the incubation time is not particularly limited, and can be, for example, 16 hours, 8 hours, 4 hours, or 2 hours.
[0070] After incubation, the mixture can be purified as necessary. The purification means is not particularly limited as long as it is capable of removing a part or all of the components other than the p53 amyloid aggregates. For example, the reaction solution after incubation can be centrifuged (for example, at 3000 to 10000 g for 1 to 60 minutes) to precipitate aggregates containing the p53 amyloid aggregates. In addition, by using the p53 amyloid aggregate-recognizing antibody of the present invention described below, it is possible to concentrate the p53 amyloid aggregates among the aggregates.
[0071] A composition containing amyloid p53 aggregates can be obtained by the aggregate production method of the present invention. Thus, in one aspect, the present invention relates to a composition containing amyloid p53 aggregates obtained by the aggregate production method of the present invention.
[0072] Furthermore, the p53 amyloid aggregate-containing composition obtained by the aggregate production method of the present invention has a higher ratio of p53 amyloid aggregates to p53 amorphous aggregates because the p53 amyloid aggregates are produced more efficiently. Therefore, in one aspect, the present invention relates to a p53 amyloid aggregate-containing composition in which the ratio (ThT / ANS) of the fluorescence intensity derived from thioflavin T (ThT) (an index of p53 amyloid aggregates) to the fluorescence intensity derived from 8-(phenylamino)-1-naphthalenesulfonic acid (ANS) (an index of p53 amorphous aggregates) is 0.5 or more.
[0073] In this specification, the above p53 amyloid aggregate-containing compositions may be collectively referred to as "the p53 amyloid aggregate-containing composition of the present invention."
[0074] ThT / ANS is preferably 0.6 or more, more preferably 0.7 or more, even more preferably 0.8 or more, still more preferably 0.9 or more, particularly preferably 1.0 or more, especially more preferably 1.2 or more, and particularly preferably 1.4 or more.
[0075] 3. Method for producing p53 amyloid aggregate-recognizing antibody In one aspect, the present invention relates to a method for producing a p53 amyloid aggregate-recognizing antibody (sometimes referred to as the "antibody production method of the present invention" in this specification), which comprises using the p53 amyloid aggregate-containing composition of the present invention as an immunogen. This will be described below.
[0076] Methods for producing antibodies are already well known, and the method for producing an antibody of the present invention can be carried out according to these conventional methods using the p53 amyloid aggregate-containing composition of the present invention as an immunogen (Current protocols in Molecular Biology, Chapters 11.12-11.13 (2000)). Specifically, when obtaining a polyclonal antibody, it is possible to immunize a non-human animal such as a rabbit with the p53 amyloid aggregate-containing composition of the present invention and obtain the antibody from the serum of the immunized animal according to a conventional method. On the other hand, when obtaining a monoclonal antibody, it is possible to obtain the antibody from hybridoma cells prepared by immunizing a non-human animal such as a mouse with the p53 amyloid aggregate-containing composition of the present invention and fusing the spleen cells obtained with myeloma cells (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley and Sons. Sections 11.4-11.11).
[0077] Antibody production can be performed by using various adjuvants depending on the host to enhance the immunological response, including, but not limited to, Freund's adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyol, polyanion, peptide, oil emulsion, keyhole limpet hemocyanin and dinitrophenol, and human adjuvants such as BCG (bacilli Calmette-Guerin) and Corynebacterium parvum.
[0078] The antibody production method of the present invention may include a purification step of the antibody, if necessary. For example, the antibody can be purified using a substance having affinity for antibodies in general, such as protein A or protein B (specifically, using a carrier to which these substances are bound), or using a p53 amyloid aggregate (specifically, the p53 amyloid aggregate-containing composition of the present invention) (specifically, using a carrier to which these substances are bound).
[0079] The antibody production method of the present invention makes it possible to obtain a p53 amyloid aggregate-recognizing antibody. Thus, in one aspect, the present invention relates to a p53 amyloid aggregate-recognizing antibody obtained by the antibody production method of the present invention.
[0080] The p53 amyloid aggregate-recognizing antibody is obtained using the p53 amyloid aggregate-containing composition of the present invention (which has a higher ratio of p53 amyloid aggregates to p53 amorphous aggregates), and therefore has a higher ability to recognize p53 amyloid aggregates relative to the ability to recognize p53 amorphous aggregates.
[0081] Furthermore, since the p53 amyloid aggregate-recognizing antibody is obtained using the p53 amyloid aggregate-containing composition of the present invention, it has a higher ability to recognize p53 amyloid aggregates than to recognize amyloid aggregates other than p53.
[0082] Therefore, the above-mentioned p53 amyloid aggregate-recognizing antibody is superior in specifically detecting p53 amyloid aggregates.
[0083] The above-mentioned p53 amyloid aggregate-recognizing antibody can be used, for example, as a medicine, a reagent, and the like.
[0084] 4. Evaluation and screening methods In one aspect, the present invention comprises: A method for evaluating a test antibody, comprising contacting the test antibody with the p53 amyloid aggregate-containing composition of the present invention; and A method for screening for a p53 amyloid aggregate-recognizing antibody, comprising contacting a test antibody with the p53 amyloid aggregate-containing composition of the present invention; Regarding.
[0085] The test antibody is not particularly limited, and may be a p53-specific antibody or a non-p53-specific antibody.
[0086] The manner of contact is not particularly limited, and is usually carried out by mixing the two in an aqueous solution.
[0087] When a test antibody binds to a p53 amyloid aggregate in a p53 amyloid aggregate-containing composition of the present invention, the test antibody can be evaluated as having p53 amyloid aggregate-binding ability and selected as a p53 amyloid aggregate-recognizing antibody.
[0088] The presence or absence of binding can be determined according to or in accordance with a known method for examining protein-protein binding.
[0089] In one aspect, the present invention also relates to a p53 amyloid aggregate-recognizing antibody selected by the above screening method. EXAMPLES
[0090] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.
[0091] Hereinafter, ANS represents 8-(phenylamino)-1-naphthalenesulfonic acid, ThT represents thioflavin T, KSCN represents potassium thiocyanate, NaSCN represents sodium thiocyanate, KI represents potassium iodide, and NaI represents sodium iodide.
[0092] In Test Example 1 and the like, the fluorescence derived from ANS is an indicator of p53 amorphous aggregates, and the fluorescence derived from ThT is an indicator of p53 amyloid aggregates (Non-Patent Document 1).
[0093] Reference Example 1. Preparation of p53 monomer BL21(DE3) E. coli strain transformed with a plasmid (pGEX6p-3-p53DBDwt) containing a sequence encoding GST tag-fused p53 (wild type)-DBD (DNA Binding Domain) was cultured in ampicillin-containing LB medium at 37°C. OD 600 At OD 0.3, ethanol was added to a final concentration of 3%, and the culture temperature was lowered to 20°C and culture was continued. 600 IPTG was added to a final concentration of 0.2 mM at pH 6.0 and cultured overnight. The collected cells were sonicated and centrifuged, and the supernatant was purified using DEAE Sepharose resin, followed by GSH Sepharose resin. The tag was cleaved using PreScission Protease, and the eluate was further purified by size exclusion chromatography. The purified protein was concentrated by ultrafiltration. The cells were stored at -80°C, and when used, they were dialyzed against assay buffer and centrifuged at 15,000g for 2 minutes at 4°C before use.
[0094] Test Example 1. Production of p53 amyloid aggregates 1 The reaction solution (aqueous solution) (composition: 4 μM p53 monomer (Reference Example 1), 20 mM HEPES-NaOH, 1 mM DTT, 10 μM ANS, 20 μM ThT, 0 to 400 mM KSCN, pH 7.4) was incubated at 37°C for 1 hour. The incubation was carried out in a quartz cell in a cell holder of a fluorescence spectrophotometer F-7000 (Hitachi High-Tech Science). The fluorescence intensity derived from ANS was measured at an excitation wavelength of 375 nm and a fluorescence wavelength of 485 nm, and the fluorescence intensity derived from ThT was measured at an excitation wavelength of 445 nm and a fluorescence wavelength of 485 nm. The fluorescence intensity was measured every 2 minutes.
[0095] The results are shown in Figure 1. It was found that the addition of KSCN suppressed the formation of p53 amorphous aggregates and promoted the formation of p53 amyloid aggregates.
[0096] Test Example 2. Production of p53 amyloid aggregates 2 The same procedure as in Test Example 1 was repeated, except that NaSCN or KI was used instead of KSCN.
[0097] The results are shown in Figures 2 and 3. It was found that the addition of NaSCN or KI inhibited the formation of p53 amorphous aggregates and promoted the formation of p53 amyloid aggregates.
[0098] Test Example 3. Production of p53 amyloid aggregates 3 The reaction solution (aqueous solution) (composition: 4 μM p53 monomer (Reference Example 1), 20 mM HEPES-NaOH, 1 mM DTT, 10 μM ANS, 20 μM ThT, 0 mM or 400 mM additive (KSCN, NaSCN, KI, or NaI), pH 7.4) was incubated at 37° C. for 1 hour. The number of n for each additive (KSCN, NaSCN, KI, or NaI) was 3. At the end of the incubation, the fluorescence intensity derived from ANS was measured at an excitation wavelength of 375 nm and a fluorescence wavelength of 485 nm, and the fluorescence intensity derived from ThT was measured at an excitation wavelength of 445 nm and a fluorescence wavelength of 485 nm. The ratio (ThT / ANS) of the measured fluorescence intensity derived from ThT (unit: au) to the measured fluorescence intensity derived from ANS (unit: au) was calculated.
[0099] In addition, since the ANS-derived fluorescence and the ThT-derived fluorescence are derived from different dyes, the difference in the fluorescence intensity between the two does not represent the difference in the amount of p53 amorphous aggregates and p53 amyloid aggregates. In other words, the above ratio (ThT / ANS) being 1 or less does not mean that the amount of p53 amyloid aggregates (reflected by the ThT-derived fluorescence intensity) is less than the amount of p53 amorphous aggregates (reflected by the ANS-derived fluorescence intensity).
[0100] The results are shown in Figure 4. Combined with the results of Test Examples 1 and 2, it was found that the addition of at least one ionic compound selected from the group consisting of thiocyanates and iodides suppressed the formation of p53 amorphous aggregates and promoted the formation of p53 amyloid aggregates.
[0101] Test Example 4: Evaluation of Residual Monomer The reaction solution (aqueous solution) (composition: 4 μM p53 monomer (Reference Example 1), 20 mM HEPES-NaOH, 1 mM DTT, 400 mM KSCN, pH 7.4) was incubated at 37° C. for 1 hour. After the incubation, the mixture was centrifuged at 15,000×g for 20 minutes to recover the supernatant. The amount of protein remaining in the supernatant was measured using a microspectrophotometer. The reaction solution before incubation was also measured in the same manner.
[0102] The results are shown in Figure 5. In the centrifugal supernatant after incubation (liquid from which aggregates had been removed), no protein-derived absorption was observed around 280 nm, indicating that no p53 protein monomers remained after incubation.
[0103] Test Example 5. Confirmation of aggregate shape 1 Incubation was carried out in the same manner as in Test Example 4, and the obtained sample was observed under a transmission electron microscope. In addition, a sample obtained in the same manner except that KSCN was not added was also observed under a transmission electron microscope.
[0104] Specifically, the elastic carbon support film was hydrophilized, the sample was attached for 2 minutes, and then uranium acetate staining solution was applied for 1 minute. Excess solution was then absorbed with filter paper, and the sample was observed using a JEM-1400PLUS.
[0105] The results are shown in Figure 6. When KSCN was added, the presence of fibrous aggregates (amyloid aggregates) was confirmed.
[0106] Test Example 6. Production and evaluation of antibodies against p53 amyloid aggregates The reaction solution (aqueous solution) (composition: 4 μM p53 monomer (Reference Example 1), 20 mM Tris-HCl, 1 mM DTT, 400 mM KSCN, pH 7.4) was filter-sterilized using a 0.2 μm filter and incubated at 37° C. for 1 hour. After incubation, the reaction solution was centrifuged at 300 g for 1 minute at 4° C., and the resulting supernatant was further centrifuged at 5000 g for 10 minutes at 4° C. Filter-sterilized buffer (20 mM Tris-HCl, 400 mM KSCN) was added to the resulting precipitate to a monomer concentration of 0.4 mg / mL, sonicated for 10 minutes, quickly frozen in liquid nitrogen, and stored frozen until antigen administration.
[0107] Using this antigen, serum containing polyclonal antibodies was obtained using Cosmo Bio's First Antibody Service (polyclonal). The serum was bound to COSMOGEL Ig-Accept Protein A resin and eluted with 0.1 M glycine-HCl, pH 2.8. The eluted solution was immediately neutralized with 2 M Tris-HCl, pH 10.4, and dialyzed overnight against PBS(-).
[0108] On the other hand, p53 amyloid aggregates were TM The mixture was mixed with NHS-Activated Agarose and incubated overnight at 4°C. After washing with PBS(-), the NHS ester was quenched with 1 M Tris-HCl, pH 7.4.
[0109] The antibody solution purified with Protein A resin was mixed with agarose bound to p53 amyloid aggregates and incubated at room temperature for 2 hours, then eluted with 0.1 M glycine-HCl, pH 2.8. The eluate was immediately neutralized with 2 M Tris-HCl, pH 10.4, and dialyzed overnight against PBS(-) to obtain the antibody against p53 amyloid aggregates (self-made antibody).
[0110] Dot blotting was performed using the self-made antibody and a commercially available p53 antibody (Pab240 antibody, manufactured by Santacruz). Specifically, the procedure is as follows. 0.5 μL of samples (p53 monomer (Reference Example 1), p53 amorphous aggregates (aggregates obtained when KSCN was not added in Test Example 5), and p53 amyloid aggregates (aggregates obtained when KSCN was added in Test Example 5)) were dropped onto the PVDF membrane, dried, and then immersed in TBS-T and incubated for 10 minutes. After that, the membrane was immersed in a 5% skim milk / TBS-T solution and incubated for 30 minutes, and then immersed in a 500-fold diluted self-made antibody solution or a 2000-fold diluted Pab240 antibody solution and incubated overnight at 4° C. After washing three times with TBS-T, the membrane was immersed in a 5000-fold diluted secondary antibody solution, incubated for 1 hour, and washed three times with TBS-T. The cells were then chemiluminesced using Chemiluminescent One Super and photographed using an imaging system.
[0111] The results are shown in Figure 7. It was found that the self-made antibody recognized p53 amyloid aggregates more strongly (more strongly than p53 amorphous aggregates) than the commercially available antibody.
[0112] Test Example 7. Confirmation of aggregate shape 2 The reaction solution (aqueous solution) (composition: 1 μM p53 monomer (Reference Example 1), 20 mM HEPES-NaOH, 1 mM DTT, 400 mM KSCN, pH 7.4) was incubated at 37° C. for 1 hour to obtain a sample.
[0113] The elastic carbon support film was hydrophilized, and the sample was attached for 2 minutes. Then, phosphotungstic acid staining solution (pH 7.0) was applied for 5 seconds. Excess solution was absorbed with filter paper, and the sample was observed using a JEM-1400PLUS.
[0114] The results are shown in Figure 8. When KSCN was added, the presence of fibrous aggregates (amyloid aggregates) was confirmed.
Claims
1. A method for producing p53 amyloid aggregates, comprising incubating a reaction solution containing a p53 protein monomer and at least one ionic compound selected from the group consisting of thiocyanate and iodide.
2. The method according to claim 1 , wherein the reaction solution contains a thiocyanate.
3. The method according to claim 1 , wherein the concentration of the ionic compound in the reaction solution is 10 mM or more.
4. The method according to claim 1 , wherein the concentration of the ionic compound in the reaction solution is 50 mM or more.
5. The method according to any one of claims 1 to 4, wherein the temperature of the reaction solution during the incubation is 10 to 50°C.
6. The method according to any one of claims 1 to 4, wherein the incubation time is 1 minute or longer.
7. A composition containing p53 amyloid aggregates, in which the ratio of the fluorescence intensity derived from thioflavin T (ThT) to the fluorescence intensity derived from 8-(phenylamino)-1-naphthalenesulfonic acid (ANS) (ThT / ANS) is 0.5 or more.
8. The p53 amyloid aggregate-containing composition according to claim 7, which contains at least one ionic compound selected from the group consisting of thiocyanate and iodide.
9. The p53 amyloid aggregate-containing composition of claim 7, wherein the ratio is 1.0 or more.
10. A p53 amyloid aggregate-containing composition obtained by the method according to any one of claims 1 to 4.
11. A method for producing a p53 amyloid aggregate-recognizing antibody, comprising using the p53 amyloid aggregate-containing composition according to any one of claims 7 to 10 as an immunogen.
12. A p53 amyloid aggregate-recognizing antibody, obtainable by the production method described in claim 11.
13. A method for evaluating a test antibody, comprising contacting the test antibody with a p53 amyloid aggregate-containing composition according to any one of claims 7 to 10.
14. A method for screening for a p53 amyloid aggregate-recognizing antibody, which comprises contacting a test antibody with the p53 amyloid aggregate-containing composition according to any one of claims 7 to 10.
15. A p53 amyloid aggregate-recognizing antibody selected by the screening method described in claim 14.
